RxDoctor Payments Data

Waqas Siddiqui, MD

Interventional Cardiology · Iowa City, IANPI 1386061729

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $6,151 of the $9,933 with a category attached, or 61.9%. 14 manufacturers reported payments, led by Medtronic at 41.6% of the total. Reporting peaked in 2023 at $3,722 and has fallen 99.2% since, to $29 in 2025.

$9,933in general payments, 2019–2025

Across 93 payments — averaging $106.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Boston Scientific$2K
  • Penumbra, Inc.$1K
  • Cardiovascular Systems Inc.$1K
  • Abbott$348
  • Biohaven Pharmaceutical Holding Company Ltd.$110
  • plus $623 from 8 others

What the payments were for

  • Travel & lodging$6,15162%
  • Food & beverage$3,50235%
  • Education$2803%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,933 in reported general payments places this provider in the 70th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$72,053
Medicare patients
553
Services billed
938

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$62,755
EntrestoSacubitril/Valsartan42$35,661
XareltoRivaroxaban28$33,396
JardianceEmpagliflozin39$30,892
BrilintaTicagrelor11$9,993
Metoprolol Succinate104$1,309
Atorvastatin Calcium96$964
Rosuvastatin Calcium45$676
Losartan Potassium34$472
ClopidogrelClopidogrel Bisulfate32$403
Chlorthalidone34$359
Ezetimibe16$294
Lisinopril59$249
Carvedilol40$216
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$104$30,89239 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →